William Blair Revises CeriBell's Q1 2025 Earnings Estimates

CeriBell, trading under the ticker symbol NASDAQ:CBLL, has recently faced a downgrade in earnings expectations from William Blair, a leading equity research firm. According to a research report published on February 26, 2025, analyst M. Andrew at William Blair now estimates that CeriBell will report earnings per share (EPS) of ($0.44) for the first quarter of 2025. This prediction marks a notable decrease from the prior estimate of ($0.30).

Despite this revision, William Blair continues to maintain an "Outperform" rating on the stock, indicating a favorable outlook compared to its peers. The consensus estimate for the company's overall earnings for the full year 2025 stands at ($2.46) per share. William Blair has also projected earnings for subsequent quarters; for Q2 2025, the estimate is set at ($0.46) EPS, followed by ($0.45) EPS for both Q3 and Q4 2025. The forecast for FY 2025 is set at ($1.81) EPS, with anticipated earnings for Q1 2026 at ($0.37) EPS and Q2 2026 at ($0.35) EPS.

Analyst Ratings and Price Targets

In addition to William Blair's analysis, other equity research analysts have offered their insights regarding CeriBell. Canaccord Genuity Group reaffirmed a "buy" rating on the company while setting a price target of $33.00. Furthermore, Bank of America initiated coverage on CeriBell on November 5, awarding it a "buy" rating and a price target of $32.00. Similarly, JPMorgan Chase & Co. began coverage on the same day, issuing an "overweight" rating with a $32.00 price target. Recently, TD Cowen elevated their price target on CeriBell from $31.00 to $36.00, also assigning a "buy" rating. Notably, six analysts have rated CeriBell as a buy, and as per MarketBeat.com, the stock holds an average rating of "Buy" with an average target price around $32.60.

CeriBell Stock Performance

As of March 1, 2025, CeriBell's stock was down by 2.2% and opened at $23.24. The stock has experienced a trading range over the last year, reaching a low of $18.69 and peaking at $32.75. Its 50-day moving average is $23.34.

Recent Financial Results

The last quarterly earnings report from CeriBell was released on February 25, 2025. The company reported a net loss of ($0.40) EPS for the quarter, falling short of the consensus estimate of ($0.32) by $0.08. Revenue for the quarter was reported at $18.53 million, surpassing analyst expectations which were set at $17.55 million.

Institutional Investment Activity

Recent changes in institutional investment have also been noted. FMR LLC made a substantial new investment in CeriBell in the fourth quarter, valued at approximately $128,120,000. Other notable acquisitions include Corebridge Financial Inc. with a new stake valued at roughly $158,000 and the Board of Trustees of The Leland Stanford Junior University purchasing shares worth around $16,143,000. Norges Bank and Next Century Growth Investors LLC also added new positions, valued at $422,000 and $5,299,000, respectively.

CeriBell Company Overview

CeriBell is recognized as a commercial-stage medical technology company with a focus on enhancing the diagnosis and management of serious neurological conditions. The company developed the Ceribell System, a cutting-edge point-of-care electroencephalography (EEG) platform aimed at addressing the unmet needs of patients receiving acute care.

Earnings, Estimates, Analysts, Stocks